# KM07 Preference Label 1 - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_247_Merrow - Task 2e5v8bf2, batch 20260612_011248).
Current status: DRAFT for platform entry.

Studio-selected pair:
- Transcript A = 0.620, 34 steps, 11m 18s.
- Transcript B = 0.400, 32 steps, 15m 34s.
- Bundle IDs not shown in the pasted transcript; record from the download icons on submit.

Evidence read: the pasted PL transcript `f9abe6b2-e91c-4160-bac5-d64157df2ed5/pasted-text.txt`, including both final output summaries. Both trajectories saw duplicate draft paths under `/docs/filesystem` and `/docs/.apps_data/calendar`, but both checked that the two draft copies were identical. For this pair, the duplicate mount is a platform hygiene issue, not a content-divergence leak.

KEY FINDING: A is better. A completes the referral letter with the major renal, infection, prednisone, cardiorenal, diabetes, gabapentin, and follow-up facts aligned to the record, and does not visibly close alendronate as a continued current medication in the final summary. B explicitly writes that "alendronate (not given inpatient) continues on its Sunday schedule," which converts the task's central open bone-health reconciliation item into a false continuation decision. A may still be incomplete if the final letter simply omits the alendronate issue rather than routing it to nephrology, so this is A2 rather than A3. The decisive gap is that B makes the central unsafe closure and A avoids that visible closure.

VERDICT: A2 (A better). Button = A+ (one plus sign).

## Justification

Preferred output: A

Transcript A is preferred because it produces the safer and more clinically faithful referral letter. It completes the medication reconciliation and restart context with the documented inpatient course for aspirin, atorvastatin, pantoprazole, carvedilol, insulin glargine, gabapentin, ferrous sulfate, calcium/vitamin D, the held cardiorenal and diabetes agents, and prednisone provenance. Most importantly, A does not visibly finalize alendronate as a current or resumed medication in the final summary. Transcript B does: it says alendronate was not given inpatient but nevertheless "continues on its Sunday schedule." That is the task's central failure pattern, because the chart leaves alendronate unadministered inpatient and unresolved for nephrology review rather than closed as continued therapy.

Justification: The grader and golden reward keeping the bone-health reconciliation open and routing it to nephrology, not turning nonadministration into a continuation plan. B commits that exact closure in the signed referral. A appears to handle the rest of the letter well and avoids the visible alendronate continuation, but the pasted evidence does not prove that A affirmatively named alendronate and routed it correctly. For that reason, A is meaningfully better rather than much better: it avoids the unsafe false closure, but may still be incomplete on the central item.

Prompt adherence: Both outputs finalize the started referral letter, preserve the letter format, remove draft status language, and save a final DOCX with a PDF copy. Both answer the requested workflow. Tie on basic prompt adherence.

Correctness: A is better. Both correctly preserve the staged restart posture for sacubitril/valsartan, spironolactone, furosemide, empagliflozin, and metformin ER, and both avoid inventing a numeric prednisone dose. B's alendronate line is the decisive correctness error. It closes a medication that was not administered inpatient as continuing on the home Sunday schedule instead of leaving the bone-health decision open for nephrology. A does not visibly make that closure in the final summary.

Completeness: B names alendronate, but names it incorrectly. A covers the major medication and follow-up domains and appears complete except for the possible omission of the bone-health reconciliation detail in the visible summary. An omitted or underdeveloped open item is less harmful than B's affirmative false continuation, so A still leads.

Methodology: Both read broadly through the chart and both recognized the duplicate mounted drafts were identical. A's synthesis stays closer to the record's unresolved-medication posture. B's methodology breaks at the key inference step by treating "not given inpatient" as compatible with simply continuing the Sunday schedule.

Quality and clarity: Both are organized and sign-ready. A is clear and clinically cautious, with appropriate caveats around last-documented values and undocumented items. B is also readable, but its clean presentation makes the alendronate error look like an accepted reconciliation decision, which is more dangerous in a referral letter.

Summary: A is preferred with A+ because B commits the central alendronate closure the task is designed to catch, while A avoids that visible unsafe closure and otherwise completes the letter soundly. The margin is A+ rather than A++ because the pasted evidence does not show A explicitly routing alendronate to nephrology; it may be an omission rather than a full catch.

## Guardrails (must survive any edit)
1. Preferred output is A.
2. Use A+ rather than A++ unless the downloaded final A letter proves A explicitly keeps alendronate open and routes it to nephrology.
3. Do not call the duplicate `.apps_data/calendar` draft a content leak in this PL pair. Both transcripts report identical draft copies.
4. The decider is B's affirmative alendronate continuation, not general prose polish or PDF formatting.
5. PL 1 of 3 required for KM07. Two more PLs on different trajectory pairs remain after this one.

## Submit Mechanics
Select A+ (one plus sign), paste the justification from "Preferred output: A" through "Summary" into Comments, submit the preference, confirm it appears in submission history, then run Preference Labels AutoQC.
